Lpi-1
Lpi-1 is an ATP-competitive LATS1/2 inhibitor with IC50 values of 4.4 nM and 1.3 nM, respectively. Lpi-1 blocks LATS-mediated YAP1 phosphorylation. Lpi-1 reversibly inhibits LATS1/2 in cells and in vivo, activating the YAP/TAZ signaling pathway. Lpi-1 can be used for research on acute liver injury and colitis.
For research use only. We do not sell to patients.
- CAS No.: 2251130-98-8
- Formula: C19H13ClFN3O2
- Molecular Weight:369.78
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All YAP Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Lats1 4.4 nM (IC50) |
Lats2 1.3 nM (IC50) |
Lats1 243.3 nM (Kd) |
Lats2 111.6 nM (Kd) |
YAP1 |
TAZ |
In Vitro
LPi-1 (15 min) is a potent ATP-competitive inhibitor of LATS1 and LATS2 in cell-free ELISA kinase assays, with IC50 values of 4.4 nM and 1.3 nM, respectively[1].
LPi-1 (30 min) binds directly to LATS1 and LATS2 with Kd values of 243.3 nM and 111.6 nM, respectively[1].
LPi-1 (100 μM) directly engages LATS1/2 and increases their thermal stability by 8.5°C and 9.5°C[1].
LPi-1 (0.1-10 μM; 1-8 h) reversibly inhibits LATS1/2, reduces YAP1/TAZ phosphorylation, and promotes nuclear YAP1/TAZ localisation and target gene expression in HepG2 cells; this effect is dose-dependent across multiple cell lines[1].
LPi-1 (10 days) promotes YAP-dependent proliferation and SOX9+/HNF4α+ biliary/progenitor transdifferentiation in primary mouse hepatocyte-derived CLiPs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 cells
-
Concentration:0.1 μM; 0.3 μM; 1 μM; 3 μM; 10 μM
-
Incubation Time:1 h; 2 h; 4 h; 5 h; 6 h; 8 h
-
Result:Reduced the phosphorylation levels of YAP1/TAZ.
-
Cell Line:HepG2 cells
-
Concentration:1 μM; 3 μM
-
Incubation Time:1 h; 2 h; 4 h; 5 h; 6 h; 8 h
-
Result:Promoted the nuclear localization of YAP1/TAZ in HepG2 cells.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t | AUC0-inf | CL | MRT0-t | MRT0-inf |
|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 5 mg/kg | i.p. | 1.27 h | 0.0830 h | 1160 ng/mL | 1190 ng·h/mL | 1200 ng·h/mL | 69.4 mL/min/kg | 0.848 h | 0.971 h |
In Vivo
Chronic LPi-1 (3 mg/kg; i.p.; once daily; 2 months) increases liver progenitor/proliferation markers and liver/body weight ratio in healthy mice, and these effects reverse after LPi-1 withdrawal[1].
LPi-1 (3 mg/kg; i.p.; once daily; 4 weeks) increases liver progenitor/proliferation markers and liver/body weight ratio in postnatal mice[1].
LPi-1 (3 mg/kg; i.p.; at surgery and twice daily; 7 days) promotes liver regeneration after partial hepatectomy by enhancing hepatocyte proliferation and YAP/TAZ activation[1].
LPi-1 (3 mg/kg; i.p.; twice daily; beginning 1.5 h after APAP) ameliorates APAP-induced acute liver injury and improves survival in mice[1].
LPi-1 (3 mg/kg; i.p.; twice daily) protects against DSS-induced colitis and preserves colonocyte proliferation in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (wild-type)[1]
-
Dosage:3 mg/kg; 0.3, 1, 3, 10, and 30 mg/kg
-
Administration:i.p.; single injection; dose-response
-
Result:Inhibition of YAP1/TAZ phosphorylation in liver reached a maximum at 2 h after i.p. injection of LPi-1 (3 mg/kg).
This inhibition in liver tissues was dose-dependent across 0.3, 1, 3, 10, and 30 mg/kg LPi-1.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, 20-25 g)[1]
-
Dosage:3 mg/kg (2 months); 3 mg/kg (2 months then withdrawal 20 days)
-
Administration:i.p.; once daily; 2 months; 20 days withdrawal
-
Result:Wild-type mice receiving LPi-1 daily for 2 months exhibited a modest increase in the percentage of CK19-positive and Ki67-positive cells, as well as in the liver/body weight ratio, which subsequently returned to baseline levels 20 days after discontinuation of LPi-1.
-
Animal Model:C57BL/6 (male, 10 days old, 8-10 g)[1]
-
Dosage:3 mg/kg
-
Administration:i.p.; once daily; 4 weeks
-
Result:LPi-1 resulted in a moderate increase in the percentage of CK19-positive and Ki67-positive cells, as well as in the liver/body weight ratio, compared with vehicle controls.
-
Animal Model:C57BL/6 (male, 8-10 weeks old, 25-30 g)[1]
-
Dosage:3 mg/kg
-
Administration:i.p.; at surgery and twice daily; 7 days
-
Result:Significantly enhanced liver regeneration, as evidenced by a higher percentage of Ki67- and BrdU-positive cells in the liver and a more rapid increase in the liver/body weight ratio compared to controls between postoperative days 1 and 7.
Mice receiving LPi-1 exhibited decreased Yap1 and TAZ phosphorylation and increased expression of Ccn2/Ctgf and Ccn1/Cyr61 between postoperative days 2 and 6.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, 20-25 g)[1]
-
Dosage:3 mg/kg
-
Administration:i.p.; twice daily; beginning 1.5 h after APAP
-
Result:In the lethal APAP model, LPi-1 increased survival from 10% to 70%.
APAP-fed mice receiving LPi-1 exhibited reduced centrilobular necrotic lesions and TUNEL+ cells at 6 h and prevented sustained expansion of necrosis at 12, 24, and 48 h.
LPi-1 lowered serum ALT and AST levels at specific hours following APAP feeding compared to controls.
-
Animal Model:C57BL/6 (male, 8-10 weeks old, 25-30 g)[1]
-
Dosage:3 mg/kg
-
Administration:i.p.; twice daily
-
Result:Mice receiving LPi-1 showed less weight loss, reduced colitis symptoms including diarrhea and rectal bleeding, more intact intestinal structure, and a higher percentage of Ki67-positive proliferating cells in colon crypts compared with vehicle controls.
Chemical Information
-
CAS No. 2251130-98-8
-
Molecular Weight 369.78
-
Formula C19H13ClFN3O2
-
SMILES
O=C(C1=COC(C2=CNC3=C2C=CC=N3)=C1)NCC4=C(Cl)C=CC=C4F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)